|
|
Vaccine Detail
|
Ankara (MVA) and ALVAC(2) Vaccine |
| Vaccine Information |
- Vaccine Name: Ankara (MVA) and ALVAC(2) Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007255
- Type: peptide
- Status: Research
- Antigen: 5T4 and gp100
- Preparation: Recombinant MVA-gp100M and ALVAC(2)-5T4 were constructed to complement existing ALVAC(2)-gp100M and MVA-5T4 vectors. Recombinant TAA expression in chicken embryo fibroblast cells was confirmed by Western blot analysis. 5T4 expression was approximately equal for both viruses, whereas ALVAC-derived gp100 was quickly degraded, at a time point when MVA-derived gp100 was still stable and expressed at high levels (Hanwell et al., 2013).
- Immunization Route: Intramuscular injection (i.m.)
- Description: This vaccine was used in clinical trials involving melanoma (Meyer et al., 2005).
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Equivalent levels of 5T4 were detected, whereas gp100M appeared to be expressed at higher levels and was more stable when vectored by MVA as opposed to ALVAC (Hanwell et al., 2013).
|
| References |
Hanwell et al., 2013: Hanwell DG, McNeil B, Visan L, Rodrigues L, Dunn P, Shewen PE, Macallum GE, Turner PV, Vogel TU. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4. Journal of immunotherapy (Hagerstown, Md. : 1997). 2013; 36(4); 238-247. [PubMed: 23603858].
Meyer et al., 2005: Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, Wölfel T. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer immunology, immunotherapy : CII. 2005; 54(5); 453-467. [PubMed: 15627214].
|
|
